



HELLENIC SOCIETY  
OF GYNECOLOGIC  
ONCOLOGY



1<sup>st</sup> DEPARTMENT OF OBSTETRICS & GYNECOLOGY,  
NATIONAL & KAPODISTRIAN UNIVERSITY OF ATHENS  
MEDICAL SCHOOL



MIDDLE EAST & MEDITERRANEAN ASSOCIATION OF  
GYNECOLOGIC ONCOLOGIST

# 8th MEMAGO

MIDDLE EAST & MEDITERRANEAN  
ASSOCIATION OF GYNECOLOGIC ONCOLOGIST

&

THE 2<sup>nd</sup> ATHENS

# OVARIAN CANCER

SYMPOSIUM

FINAL PROGRAM

**ATHENS**  
ROYAL OLYMPIC HOTEL

**28-30**  
NOVEMBER

▽ **Jemperli**  
(dostarlimab) Injection 500 mg

**Zejula**  
niraparib  
tablets 100 mg

#### ZEJULA - ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:

Το κάθε επικαλυμμένο με λεπτό υμένιο δισκίο περιέχει μονοδερική τοσουλική νιραπαρίμπη που ισοδυναμεί προς 100 mg νιραπαρίμπη.

Λιανική Τιμή: 3764,13€

% επικορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100% , κατόπιν ένταξης του προϊόντος στον Κατάλογο Αποζημιούμενων Φαρμάκων. Περιορισμένη ιατρική συνταγή. Η ένταξη της Θεραπείας γίνεται σε νοσοκομείο και μπορεί να συνεχίζεται εκτός νοσοκομείου υπό την παρακολούθηση ειδικού ιατρού.

Πριν τη συνταγογράφηση, συμβουλευτείτε την Περίληψη των Χαρακτηριστικών του Προϊόντος η οποία είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.

Τα εμπορικά σήματα ανήκουν ή έχουν παραχωρηθεί στον Όμιλο εταιρειών GSK. ©2024 Όμιλος εταιρειών GSK ή δικαιούχος του Όμιλου GSK.

Τα ανωτέρω ισχύουν κατά την ημερομηνία σύνταξης του υλικού. Παρακαλούμε επικοινωνήστε με την εταιρεία για επιβεβαίωση πλήρους ενημερωμένων δεδομένων, για οποιαδήποτε πληροφορία ή/και αναφορά Ανεπιθύμητων Ενεργειών στο τηλέφωνο 210 6882100.

#### JEMPERLI - ΠΟΙΟΤΙΚΗ ΚΑΙ ΠΟΣΟΤΙΚΗ ΣΥΝΘΕΣΗ:

Ένα φιαλίδιο πυκνού διαλύματος για παρασκευή διαλύματος προς έγχυση των 10 ml περιέχει 500 mg dostarlimab. Κάθε ml πυκνού διαλύματος για παρασκευή διαλύματος προς έγχυση περιέχει 50 mg dostarlimab. Το dostarlimab είναι ένα ανθρωποποιημένο μονοκλωνικό αντίσωμα (mAb) ανοσοσφαιρίνης G4 (IgG4) κατά της πρωτεΐνης προγραμματισμένου κυτταρικού θανάτου-1 (PD-1), παράγεται με τεχνολογία ανασυνδυασμένου DNA σε κύτταρα ωσθηκών κινεζικού κρικητού (CHO).

Λιανική Τιμή: 6011,33€

% επικορήγησης από τους οργανισμούς κοινωνικών ασφαλίσεων: 100% , κατόπιν ένταξης του προϊόντος στον Κατάλογο Αποζημιούμενων Φαρμάκων. Μόνο για νοσοκομειακή χρήση από γιατρό με κατάλληλη ειδικευση και εμπειρία.

Πριν τη συνταγογράφηση, συμβουλευτείτε την Περίληψη των Χαρακτηριστικών του Προϊόντος η οποία είναι διαθέσιμη κατόπιν αιτήσεως στην εταιρεία.

▽ Το φάρμακο αυτό τελεί υπό συμπληρωματική παρακολούθηση. Αυτό θα επιτρέψει τον γρήγορο προσδιορισμό νέων πληροφοριών ασφάλειας. Ζητείται από τους επαγγελματίες υγείας να αναφέρουν οποιαδήποτε πιθανολογούμενες αν επιθυμητες ενέργειες. Βλ. παράγραφο 4.8 για τον τρόπο αναφοράς ανεπιθύμητων ενεργειών.

Βοηθήστε να γίνουν τα φάρμακα πιο ασφαλή και  
Αναφέρετε  
ΟΛΕΣ τις ανεπιθύμητες ενέργειες για  
ΟΛΑ τα φάρμακα  
Συμπληρώνοντας την "ΚΙΤΡΙΝΗ ΚΑΡΤΑ"



www.kitrikinikarta.gr

**GlaxoSmithKline** ΜΟΝΟΠΡΟΣΩΠΗ Α.Ε.Β.Ε  
Λ. Κηφισίας 266, 15232 Αθήνα, Τηλ. 210 6882100  
[www.gr.gsk.com](http://www.gr.gsk.com)

**GSK**

Η υγεία κάθε άνδρα και κάθε γυναίκας  
είναι για εμάς...

ΤΟ & ΤΟ  
ΙΑΣΩ

Στο ΙΑΣΩ Γενική Κλινική, παρέχουμε ολοκληρωμένες υπηρεσίες υγείας, ακολουθώντας τις πιο σύγχρονες μεθόδους διάγνωσης και θεραπείας. Με έμπειρους γιατρούς όλων των ειδικοτήτων, πρωτοποριακό ιατροτεχνολογικό εξοπλισμό και μοντέρνες εγκαταστάσεις, το ΙΑΣΩ Γενική Κλινική αποτελεί την πρώτη επιλογή στην κορυφαία φροντίδα για άνδρες και γυναίκες κάθε ηλικιακής ομάδας.

**Γιατί στόχος μας είναι να φροντίζουμε την υγεία σας, που για εμάς είναι το Α και το Ω.**

Λεωφ. Κηφισίας 37-39, 151 23, Μαρούσι Αττικής

Τηλ: 210 6184000 / Fax: 210 6184158

Email: [info@iaso.gr](mailto:info@iaso.gr)

[www.iaso.gr](http://www.iaso.gr)

    [omilosiaso](https://www.facebook.com/omilosiaso)  [group-iaso](https://www.linkedin.com/company/group-iaso)

 **ΙΑΣΩ** Γενική Κλινική

Για ό,τι πιο πολύτιμο έχεις.

## Middle East & Mediterranean Association of Gynecologic Oncologist

### BOARD OF DIRECTORS

**President**

Mehmet Faruk Köse, TÜRKİYE

**Vice President**

Nejat Özgül, TÜRKİYE

**Secretary**

Mehmet Mutlu Meydanlı, TÜRKİYE

**Treasurer**

Çağatay Taşkiran, TÜRKİYE

**Members**

Macit Arvas, TÜRKİYE

Mete Güngör, TÜRKİYE

Müfit Cemal Yenen, TÜRKİYE

Hüsnü Çelik, TÜRKİYE

**Co-President**

Georges Chahine, LEBANON

**Co-Vice President**

Muhieddine Seoud, LEBANON

**Co-Secretary**

David Atallah, LEBANON

**Co-Treasurer**

Monia Hechiche, TUNISIA

**Co-Members**

Basel Refky, EGYPT

Waleed AlJassar, KUWAIT

Alexandros Rodolakis, GREECE

Jamel Ben Hassouna, TUNISIA

**CONGRESS PRESIDENT**

Alexandros Rodolakis, GREECE

## Hellenic Society of Gynecologic Oncology

### BOARD OF DIRECTORS

**Rodolakis Alexandros**, GREECE

**Haidopoulos Dimitrios**, GREECE

**Thomakos Nikolaos**, GREECE

**Papathedorou Dimitrios**, GREECE

**Tsolakidis Dimitrios**, GREECE

**Petousis Stamatios**, GREECE

**Kalogiannidis Ioannis**, GREECE

**CONGRESS PRESIDENTS**

Dimitrios Haidopoulos, Michael Liontos  
GREECE

# Aptima<sup>®</sup> HPV Assay



Ιδανικά τι πρέπει να ανιχνεύει το HPV Test;

Τη φάση της HPV λοίμωξης που μπορεί να οδηγήσει σε ανάπτυξη καρκίνου τραχήλου μήτρας<sup>1</sup>

- Οι μελέτες έχουν δείξει ότι η έκφραση του mRNA των E6/E7 δηλώνει την ενεργό HPV λοίμωξη
- Η ανίχνευση των E6/E7 mRNA των ιών υψηλού κινδύνου υποδηλώνει ότι η λοίμωξη μπορεί να οδηγήσει σε καρκινογένεση

## Aptima<sup>®</sup> mRNA HPV Test

Το πλέον αποτελεσματικό στην ασφαλή πρόληψη του καρκίνου του τραχήλου της μήτρας<sup>2, 3, 4</sup>

- Επιτυγχάνει την ανίχνευση των E6/E7 mRNA των 14 ιών υψηλού κινδύνου
- Επιτρέπει την τυποποίηση των E6/E7 mRNA των πλέον ογκογόνων τύπων HPV (16, 18 και 45)

# E6 E7

Ο συνδυασμός ThinPrep<sup>®</sup> Παπ Τεστ και Aptima<sup>®</sup> mRNA HPV Test αποτελεί την πλέον αξιόπιστη προστασία των γυναικών από τον καρκίνο τραχήλου της μήτρας.<sup>5</sup>



### Βιβλιογραφία:

1. Haedicke, J. (2016). Journal of Clinical Microbiology, 76, S40-S48.
2. Aptima HPV Assay. Package Insert
3. Smith, JS. (2007). Int J Cancer, 121(3):621-32.
4. De Sanjose S, et al. (2010). Lancet Oncol, 11:1048-56
5. Saslow D. (2012). J. Low Genit Tract Dis., 16(3):175-204.

# Aptima<sup>®</sup> HPV Assay



**8th MEMAGO**  
MIDDLE EAST & MEDITERRANEAN  
ASSOCIATION OF GYNECOLOGIC ONCOLOGIST &

THE 2<sup>nd</sup> ATHENS  
**OVARIAN CANCER**

ATHENS  
ROYAL OLYMPIC HOTEL

SYMPOSIUM

**28-30**  
NOVEMBER

## 8<sup>th</sup> MEMAGO

### I N T R O D U C T I O N

Dear Colleagues,

It is with great pleasure, and on behalf of the Organizing Committee, that I announce the organization of the **8<sup>th</sup> Annual Congress of the Middle East and Mediterranean Association of Gynecologic Oncologists**.

The **Middle East & Mediterranean Association of Gynecologic Oncologist (MEMAGO)** was established in 2015 with the aim of increasing awareness in the management of gynecologic cancers in the Middle East and the Mediterranean, providing educational activities through national and international meetings, and improving the prevention of gynecologic malignancies and the evidence-based management of gynecologic cancers.

The conference is held annually in a different country in the Mediterranean, and this year it is an honor, as well as a unique opportunity, that it will take place in our country from **November 28-30** in Athens at the Athens Royal Olympic Hotel.

Renowned International and Greek Speakers will share the latest scientific developments in Gynecologic Oncology covering the following main topics:

- Prevention and Screening of Cervical Cancer
- Cervical Cancer
- Uterine Neoplasms - Endometrial Cancer
- Uterine Neoplasms - Uterine Sarcoma
- Sexuality and Gynecologic Cancers
- Vulvar Cancer
- Epithelial Ovarian Cancer

We hope to have your active participation in the conference proceedings, and we thank you for your continued positive response.

With regards

**Alexandros Rodolakis**

President of Hellenic Society of Gynecologic Oncology  
Chairman of the 8th MEMAGO Organizing Committee

## 2<sup>nd</sup> Athens Ovarian Cancer Symposium

### I N T R O D U C T I O N

Dear Colleagues,

It is our great pleasure to invite you to attend the **2<sup>nd</sup> Athens Ovarian Cancer Symposium** held on the **29<sup>th</sup> and 30<sup>th</sup> of November, 2024**.

The Symposium focuses emphatically on ovarian cancer and is **organized by the Division of Gynecologic Oncology of the 1<sup>st</sup> Department of Obstetrics and Gynecology of the University of Athens, and the Hellenic Society of Gynecologic Oncology**.

In recent years, the alternative management strategies for ovarian cancer have

multiplied as not only the surgical techniques have evolved but novel treatments such as target therapies and immunotherapy have been integrated in our armamentarium.

The combination of surgery, chemotherapy, administration of PARP inhibitors and antiangiogenic agents has led to a new era of treatment for this heterogeneous disease.

You will have the opportunity to attend lectures from Greek and Foreign experts (Gynecologic and Clinical Oncologists) who have a special interest in the field of ovarian cancer. The topics will cover all the emerging and promising fields from both surgical and oncological aspects for Ovarian Cancer patients. Included is a special Session entitled: **"Is Endometrial Cancer the New Ovarian Cancer?"** as the new developments in the treatment of advanced endometrial cancer are similar to the ovarian cancer treatments.

**We invite you to actively participate** by expanding your knowledge regarding the latest developments in the field of ovarian cancer and thus contributing to the success of the Symposium.

Symposium Presidents

**Dimitrios Haidopoulos**

As. Professor  
in Gynecological Oncology

**Michael Liontos**

As. Professor  
in Clinical Oncology

# Medtronic

Cordless freedom —  
plus so much more.



Still the first and only cordless ultrasonic dissector, the Sonicision™ 7 curved jaw device now gives you the ability to coagulate vasculature up to and including 7 mm in diameter.<sup>1</sup>

1. Sonicision™ 7 Cordless Ultrasonic Dissection System [user's guide]. Minneapolis, MN: Medtronic, 2021.



**DAY 1, NOVEMBER 28, 2024**

**09:30-09:45 WELCOME AND INTRODUCTION**

**MEMAGO** President Mehmet Faruk Köse (Turkey)  
Local Organizing Committee Chair Alexandros Rodolakis (Greece)

**SESSION 1: PREVENTION AND SCREENING OF CERVICAL CANCER**

*Chairs: U. Firat Ortaç (Turkey), Omar Alelwan (Jordan), Evangelos Paraskevaïdis (Greece)*

- 09:45-10:00 **Cervical cancer screening strategies in the MEMAGO region**  
Nadine El Kassis (Lebanon)
- 10:00-10:15 **HPV DNA - mRNA - self testing**  
Alexandros Daponte (Greece)
- 10:15-10:30 **HPV vaccination: An update**  
Mehmet Faruk Köse (Turkey)
- 10:30- 10:45 **Medical Treatment of HPV Infection**  
Murat Gültekin (Turkey)

**10:45-11:00 COFFEE BREAK**

**Session 2: Cervical cancer**

*Chairs: Kostantinos Dinas (Greece), Esra Kuşcu (Turkey), Jamel Ben Hassouna (Tunisia)*

- 11:00-11:15 **Less radical surgery for early-stage cervical cancer: Efficacy and safety**  
Nikolaos Thomakos (Greece)
- 11:15-11:30 **Minimally invasive surgery (MIS) for early-stage cervical cancer: Is it safe?**  
Maher Slimane (Tunisia)
- 11:30-11:45 **Adjuvant treatment for surgically treated patients**  
Stamatios Petousis (Greece)
- 11:45-12:30 **Treatment of Stage IB2/IB3 Cervical Cancer**
- 11:45-12:00 - **NACT** - Özden Altundağ (Turkey)
- 12:00-12:15 - **Surgery** - Olfa Jaidane (Tunisia)
- 12:15-12:30 - **Chemo-Concurrent Radiation Therapy** - Athanassios Dimopoulos (Greece)
- 12:30- 12:45 **Fertility sparing surgery for Stage IB2 cervical cancer**  
Alexandros Rodolakis (Greece)
- 12:45- 13:00 **Exenterative surgery in cervical cancer patients: Indications and technique**  
Greta Dreyer (South Africa)
- 13:00-13:15 **Discussion**
- 13:15-13:30 **Ali Ayhan Memorial**  
Mehmet Mutlu Meydanlı (Turkey)

**13:30 -14:30 LUNCH**





**DAY 1, NOVEMBER 28, 2024**

**Session 3: Uterine Neoplasms - Endometrial Cancer**

*Chairs: Mehmet Mutlu Meydanlı (Turkey), Waleed Elnahas (Egypt), Emmanuel Kalampokas (Greece)*

- 14:30-14:45 **The new FIGO Staging in Endometrial Cancer in the modern era of Molecular Classification Pitfalls and challenges**  
Frederic Amant (Belgium) - *Web participation*
- 14:45-15:00 **Management of advanced and recurrent endometrial cancer: The emerging role of immunotherapy**  
Roland Eid (France)
- 15:00-15:15 **Fertility sparing treatment for endometrial cancer patients: Patient selection, treatment and follow-up**  
David Atallah (Lebanon)
- 15:15-15:30 **Principles of MIS in endometrial cancer**  
Çağatay Taşkiran (Turkey)
- 15:30-15:45 **Discussion**

**15:45-16:15 COFFEE BREAK**

**Session 4: Uterine Neoplasms - Uterine Sarcoma in the light of new ESGO guidelines**

*Chairs: Mehmet Mutlu Meydanlı (Turkey), Monia Hechiche (Tunisia), Christos Papatimitriou (Greece)*

- 16:15-16:30 **Advances in the preoperative work-up of suspected uterine sarcomas**  
Hüseyin Akıllı (Turkey)
- 16:30-16:45 **Principles of surgery for uterine sarcomas**  
Ignacio Zapardiel (Spain)
- 16:45-17:00 **Adjuvant treatment for leiomyosarcomas and high-grade sarcomas**  
Isabelle Ray-Coquard (France) - *Web participation*
- 17:00-17:15 **Management of recurrent uterine sarcomas**  
Isabelle Ray-Coquard (France) - *Web participation*
- 17:15-17:45 **Discussion**

**Session 5: Sexuality and gynecologic cancers**

*Chairs: Dimitrios Papatheodorou (Greece), Murat Gültekin (Turkey)*

- 17:45-18:05 **Sexual health in gynecologic cancer survivors**  
Nadine El Kassis (Lebanon)

**18:05 Adjourn**



**DAY 2, NOVEMBER 29, 2024**

**Session 1: Vulvar cancer**

*Chairs: Georgios Vorgias (Greece), Zannis Voulgaris (Greece)*

- 09:30-09:45 **Early-stage disease: Individualization of treatment**  
Ioannis Kalogiannidis (Greece)
- 09:45-10:15 **Management of advanced vulvar cancer**
- 09:45-10:00 - **Primary surgical management** - Montassar Ghaleb (Tunisia)
- 10:00-10:15 - **The role of NACT - CRT** - Naemat Hegazy (Egypt)
- 10:15 - 10:30 **Discussion**

**Session 2: Epithelial Ovarian Cancer (EOC) - I**

*Chairs: İkbal Yüksel (Turkey), Mazen Bishtawi (Jordan), Alexandros Rodolakis (Greece)*

- 10:30 -10:45 **Management of borderline ovarian tumors**  
Vasileios Sioulas (Greece)
- 10:45 -11:00 **Genetic testing and counselling for EOCs**  
Sarah Alrubaish (Saudi Arabia)
- 11:00 -11:15 **Fertility sparing options in EOC: Patient selection and feasibility**  
Philippe Morice (France)
- 11:15 -11:30 **Treatment of Low-grade serous ovarian carcinoma**  
Dimitrios Haidopoulos (Greece)
- 11:30 -11:45 **Discussion**

**11:45-12:00 COFFEE BREAK**

**Session 3: Ali Ayhan Memorial Ovarian cancer session**

*Chairs: Nejat Özgül (Turkey), Dimitrios Haidopoulos (Greece), Athanasios-Meletios Dimopoulos (Greece)*

- 12:00-12:15 **Primary management of advanced EOC**  
**Up front surgery with primary cytoreduction**  
Konstantinos Lathouras (Greece)
- 12:15-12:30 **NACT - Optimal timing of interval debulking surgery in advanced ovarian cancer**  
Frédéric Guyon (France)
- 12:30-12:45 **Adjuvant and maintenance treatment in Epithelial Ovarian cancer**  
Christos Papadimitriou (Greece)
- 12:45-13:00 **Immunotherapy and Antibody Drug Conjugates (ADCs): How far are we from clinical application?**  
Georges Chahine (Lebanon)
- 13:00-13:15 **Discussion**

**13:15-14:30 LUNCH**



**DAY 2, NOVEMBER 29, 2024**

**Session 4: Epithelial Ovarian Cancer (EOC) - Debates**

*Chairs: Çağatay Taşkıran (Turkey), Alexios Papanikolaou (Greece), Michael Liontos (Greece)*

- 14:30-15:00 **The role of MIS in the management of ovarian cancer**
- 14:30-14:45 - **PRO MIS** - Refky Basel (Egypt)
- 14:45-15:00 - **PRO open surgery** - Dimitrios Tsolakidis (Greece)
  
- 15:00-15:30 **HIPEC in the frontline management of EOC?**
- 15:00-15:15 - **PRO** - Alain Daher (Lebanon)
- 15:15-15:30 - **CON** - Theodore Panoskaltzis (Greece)
  
- 15:30-15:45 **Can we define unified consensus for the management of ovarian cancer in the MEMAGO region**
- Noha Rashad (Egypt)
- 15:45-16:00 **Discussion**

**16:00 Closing Ceremony of the 8<sup>th</sup> MEMAGO Annual Congress**



**THE 2<sup>nd</sup> ATHENS**  
**OVARIAN CANCER SYMPOSIUM**

**28-30**  
 NOVEMBER 2024  
 Greece, Athens

**17:45 - 18:00 WELCOME**  
 Introduction 2<sup>nd</sup> Athens Ovarian Cancer Symposium

**18:00 – 18:30 Satellite Symposium I**  
*Chairs: D. Haidopoulos (Greece), V. Hatzirafail (Greece), C. Iavazzo (Greece)*

*sponsored by*



**The use of robotic surgery in ovarian neoplasms**  
 D. Bolovis (Greece)

**18:30 – 20:00 Session 1: Molecular Profiling and Pathology**  
*Chairs: A. Anagnostopoulos (Greece), G. Daskalakis (Greece), V. Sioulas (Greece)*

- 18:30 – 18:45 **Is there a place for molecular screening in ovarian cancer?**  
 R. Zakopoulou (Greece)
- 18:45 – 19:00 **Histopathological classification of epithelial and non-epithelial tumors: novel aspects and impact on management**  
 M. Sotiropoulou (Greece)
- 19:00 – 19:15 **Molecular biomarkers in Ovarian Cancer – HRD**  
 P. Constantoulakis (Greece)
- 19:15 – 19:30 **Genetic counseling and prophylactic treatment**  
 F. Fostira (Greece) - *Web participation*
- 19:30 – 20:00 **Discussion**

# THE 2<sup>nd</sup> ATHENS OVARIAN CANCER SYMPOSIUM

**28-30**  
NOVEMBER 2024  
Greece, Athens

**DAY 3, NOVEMBER 30, 2024**

## **09:00 – 10:45 Session 2: Peri-operative Issues in Ovarian Cancer Surgery**

*Chairs: K. Lathouras (Greece), G.M Makris (Greece), N. Thomakos (Greece)*

### **09:00 – 09:15 ERAS pathways in ovarian cancer surgery**

G. Nelson (Canada) - *Web participation*

### **09:15 – 09:30 Peri-operative management in ovarian cancer patients**

D. Haidopoulos (Greece)

### **09:30 – 09:45 Reproductive considerations, safety and feasibility of IVF following treatment for early-stage ovarian cancer**

Th. Papageorgiou (Greece)

### **09:45 – 10:00 Quality of life and sexuality post ovarian cancer surgery**

M. Gultekin (Turkey)

### **10:00 – 10:15 Anaesthetic considerations and frailty scores for patients' stratification prior to surgery**

E. Stamatakis (Greece)

### **10:15 – 10:45 Discussion**

## **10:45 – 12:30 Session 3: Surgical Considerations**

*Chairs: N. Alexakis (Greece), A. Protopapas (Greece), A. Rodolakis (Greece)*

### **10:45 – 11:00 Fertility-sparing surgery in non-epithelial ovarian cancer**

N. Akrivos (Greece)

### **11:00 – 11:15 MIS in relapsed ovarian cancer**

I. Zapardiel (Spain)

### **11:15 – 11:30 Upper abdominal debulking: limits and surgical techniques**

C. Taşkıran (Turkey)

### **11:30 – 11:45 Management of nodal disease**

I. Zapardiel (Spain)

### **11:45 – 12:00 Surgery for first platinum-sensitive relapse – the CHIPOR study**

F. Guyon (France)

### **12:00 – 12:15 Specificities about surgical management of mucinous tumors**

P. Morice (France)

### **12:15 – 12:30 Discussion**

## **12:30 – 13:00 Satellite Symposium II**

*Chairs: C. Christodoulou (Greece), D. Haidopoulos (Greece)*

*sponsored by*



**The value of MDT approach for Patients with Gynecological Cancer.**

**The implication of referring patients to ESGO certified centers, in order to achieve Better Quality of Care.**

**The Gynecological Oncologist perspective: V. Pergialiotis (Greece)**

**The Oncologists perspective: M. Liontos (Greece)**

## **13:00 – 13:30 COFFEE BREAK**



# THE 2<sup>nd</sup> ATHENS OVARIAN CANCER SYMPOSIUM

28-30  
NOVEMBER 2024  
Greece, Athens

DAY 3, NOVEMBER 30, 2024

**13:30 – 14:00** **Satellite Symposium III**

sponsored by



*Chairs: D. Haidopoulos (Greece), M. Liontos (Greece)*

**New therapeutic approaches & dilemmas for the management of patients with pMMR & dMMR Metastatic Endometrial Cancer**

J. Syrios (Greece)

**14:00 – 15:30** **Session 4: Is Endometrial Cancer the New Ovarian Cancer?**

*Chairs: G. Androutsopoulos (Greece), T. Panoskaltis (Greece)*

14:00 – 14:15 **Does molecular profiling has an impact on adjuvant RTX treatment?**

A. Dimopoulos (Greece)

14:15 – 14:30 **Management of MMR deficient recurrent metastatic disease**

D. Lorusso (Italy) - *Web participation*

14:30 – 14:45 **NACT in advanced endometrial Ca**

M. Liontos (Greece)

14:45 – 15:00 **Surgery in advanced endometrial Ca**

F. Guyon (France)

15:00 – 15:15 **The patient's perspective**

M. Papageorgiou (Greece) - *Web participation*

15:15 – 15:30 **Discussion**

**15:30 – 16:00** **COFFEE BREAK**

**16:00 – 18:00** **Session 5: Systemic Therapy in Ovarian Cancer**

*Chairs: E. Lianos (Greece), Ch. Theofanakis (Greece), G. Vlachos (Greece)*

16:00 – 16:15 **Systemic therapy in early and advanced disease**

K. Koutsoukos (Greece)

16:15 – 16:30 **Mechanisms of PARP resistance**

I. Labidi - Galy (Switzerland) - *Web participation*

16:30 – 16:45 **Treatment of recurrent disease**

O. Fiste (Greece)

16:45 – 17:00 **Immunotherapy and novel target agents in AOC**

A. M. Nikolaidi (Greece)

17:00 – 17:45 **Real world data in ovarian cancer**

D. Vlachos (Greece) – K. Angelou (Greece) - A. Andrikopoulou (Greece)

17:45 – 18:00 **Discussion**

**18:00** **CLOSING REMARKS**

## PRESIDENTS-SPEAKERS

NAME	COUNTRY	PROFESSIONAL TITLE / AFFILIATION
<b>AKILLI HUSEYIN</b>	TURKEY	
<b>AKRIVOS NIKOLAOS</b>	GREECE	RCOG/ESGO Gynecologist Oncologist, Director of the 3rd Gynecological Oncology Clinic, 'Hygeia' Hospital, Head of the Fertility Preservation Department for Women with Malignancy, 'Mitera' Hospital, Doctor of Medicine, National and Kapodistrian University of Athens
<b>AL RUBAISH SARAH</b>	SAUDI ARABIA	MD, Gynecology Oncology, Dr. Suliman Al-Habib Eastern Provence Alkhuber
<b>ALELWAN OMAR</b>	JORDAN	MD
<b>ALEXAKIS NIKOLAOS</b>	GREECE	Professor of Surgery, National and Kapodistrian University of Athens
<b>ALTUNDAG OZDEN</b>	TURKEY	MD, Professor of Medical Oncology, Beşkent University, Ankara, Turkey
<b>AMANT FREDERIC</b>	BELGIUM	MD, PhD, Professor in Gynaecological Oncology, University Hospital Leuven, Belgium
<b>ANAGNOSTOPOULOS ANTONIOS</b>	GREECE	MRCOG, CCT, Gynecological Oncological Surgeon, RCOG-ESGO certified, First Assistant of the Gynecology Department, 'Agius Savvas' Oncology Hospital
<b>ANDRIKOPOULOU AGGELIKI</b>	GREECE	MD, PhD, Resident in Medical Oncology, "Alexandra" University Hospital, Athens
<b>ANDROUTSOPOULOS GEORGIOS</b>	GREECE	Associate Professor of Obstetrics & Gynecology, Head of the Gynecological Oncology Unit, Obstetrics & Gynecology Clinic, University of Patras
<b>ANGELOU KYVELI</b>	GREECE	Scientific Associate, Obstetrician-Gynecologist, 1st Obstetrics & Gynecology Clinic, "Alexandra" Hospital
<b>ATALLAH DAVID</b>	LEBANON	M.D., M.Sc., Professor of Obstetrics and Gynecology, Chairman of Department, Gynecology and Abnormal Placentation, Gynecologic Oncology and Breast Surgery Urogynecology, IGCS board of Directors, Secretary Treasurer Elect, Secretary General of MEMAGO, President Lebanese Society of Obstetrics and Gynecology, Editor-In Chief, Lebanese Medical Journal, Lebanon
<b>BASEL REFKY ABDEL FATTAH AHMED</b>	EGYPT	MD, MRCS, EBSQ, European Board of Surgical Oncology, Associate Professor of Surgical Oncology, Oncology Center, Mansoura University, Egypt
<b>BEN HASSOUNA JAMEL</b>	TUNISIA	
<b>BISHTAWI MAZEN</b>	JORDAN	FACOG, FRCOG, MD, Head of Women Services, The View Hospital affiliated with Cedar Sinai, Associate Professor, College of Medicine. Qatar University
<b>BOLOVIS DIMITRIOS</b>	GREECE	Prof. Dr. Med
<b>CHAHINE GEORGES</b>	LEBANON	Treasurer of MEMAGO
<b>CHRISTODOULOU CHRISTOS</b>	GREECE	Pathologist-Oncologist, Director of the 2nd Oncology Clinic, Metropolitan Hospital
<b>CONSTANTOULAKIS PANTELIS</b>	GREECE	PhD, Molecular Biologist - Geneticist, Scientific Director of Medical Center "GENOTYPOS SCIENCE LABS"
<b>DAHER ALAIN</b>	LEBANON	
<b>DAPONTE ALEXANDROS</b>	GREECE	Professor of Obstetrics & Gynecology, University of Thessaly, Director of the Obstetrics & Gynecology Clinic, University of Thessaly, University Hospital of Larissa, Larissa
<b>DASKALAKIS GEORGIOS</b>	GREECE	Professor of Obstetrics Gynecology-FetoMaternal and Perinatal Medicine, Alexandra Hospital, National and Kapodistrian University of Athens, Greece
<b>DIMOPOULOS ATHANASIOS</b>	GREECE	Radiation Oncologist, Director and Coordinator of the Radiotherapeutic Oncology Center, Metropolitan Hospital, Venia Docendi of the University of Vienna, ESTRO Faculty Member
<b>DIMOPOULOS MELETIOS-ATHANASIOS</b>	GREECE	Professor of Therapeutics-Hematology-Oncology, Medical School, National and Kapodistrian University of Athens, Director of the Therapeutic Clinic, Alexandra Hospital
<b>DINAS KONSTANTINOS</b>	GREECE	Professor of Obstetrics-Gynecology-Gynecological Oncology, Director of the 2nd Obstetrics-Gynecology Clinic, Aristotle University of Thessaloniki, Thessaloniki

## PRESIDENTS-SPEAKERS

NAME	COUNTRY	PROFESSIONAL TITLE / AFFILIATION
<b>DREYER GRETA</b>	SOUTH AFRICA	Professor, Gynaecologic Oncology Unit, University of Pretoria, South Africa
<b>ROLAND EID</b>	FRANCE	MD, MSc, MPH, Medical Oncologist and Hematologist, Hôtel-Dieu de France University Hospital, Saint Joseph University of Beirut
<b>EL KASSIS NADINE</b>	LEBANON	MD, MSc, Gynecologic Oncology, Hotel Dieu de France Hospital, Beirut, Saint Joseph University, Beirut
<b>ELNAHAS WALEED</b>	EGYPT	Professor of Surgical Oncology, Oncology Center, Mansoura University, Egypt
<b>FISTE ORAIANTHI</b>	GREECE	MD, MSc, PhD, Medical Oncologist, 3rd Department of Internal Medicine & Laboratory, Medical School of Athens, National and Kapodistrian University, Thoracic General Hospital of Athens "I SOTIRIA"
<b>FOSTIRA FLORENTIA</b>	GREECE	Dr., ErCLG, Clinical Laboratory Geneticist
<b>GULTEKIN MURAT</b>	TURKEY	MD, Professor, Chair of ESGO Prevention Committee, Turkey
<b>GUYON FREDERIC</b>	FRANCE	MD, Head of Surgical Department Bergonie Institute, Team 2 Inserm Reprograming Tumor Activity (RYTME) Bordeaux Institute of Oncology
<b>HAIDOPOULOS DIMITRIOS</b>	GREECE	Ass. Professor of Gynecological Oncology, University of Athens
<b>HATZIRAFAIL VASSILIKI</b>	GREECE	Obstetrician-Surgeon Gynecologist, Director of the Gynecological-Oncological Clinic, Euroclinic of Athens
<b>HECHICHE MONIA</b>	TUNISIA	Surgeon Oncologist, President of the STCO (Tunisian Society of Surgical Oncology)
<b>HEGAZY NEAMAT</b>	EGYPT	Ass. Professor of Clinical Oncology, Alexandria University, Egypt
<b>IVAZZO CHRISTOS</b>	GREECE	Gynecological Oncologist - Head of Gynecologist Physicians, "Henri Dunant" Hospital, First Assistant of the Gynecology Clinic, 'Metaxa' General Oncology Hospital
<b>JAIDANE OLFA</b>	TUNISIA	MD, Associate Professor in Surgical Oncology, Surgical Oncology Department, Salah Azaiez Institute of Tunis, Faculty of Medicine of Tunis
<b>KALAMPOKAS EMMANUEL</b>	GREECE	MSc, PhD, RCOG, Obstetrician - Gynecological Surgeon, RCOG/ESGO Gynecological Oncologist, Assistant Professor of Obstetrics & Gynecology, National and Kapodistrian University of Athens
<b>KALOGIANNIDIS IOANNIS</b>	GREECE	Associate Professor of Obstetrics and Gynecology - Gynecological Oncology, Aristotle University of Thessaloniki, 3rd Obstetrics-Gynecology Clinic, Hippokration Hospital, Thessaloniki
<b>KOSE M. FARUK</b>	TURKEY	MD, Professor of Obstetrics and Gynecology and Gynecologic Oncology, Acibadem University School of Medicine, Department of Obstetrics and Gynecology and Gynecologic Oncology, Istanbul, Turkey, President of MEMAGO
<b>KOUTSOUKOS KONSTANTINOS</b>	GREECE	Pathologist Oncologist, "Alexandra" Hospital, Scientific Director of the Oncology Department at Evgenideio Therapeutic Center
<b>KUSCU ESRA</b>	TURKEY	MD, Professor Başkent University School of Medicine, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology
<b>LABIDI - GALY INTIDHAR</b>	SWITZERLAND	MD, PhD, Professor, President of the SAKK gynecological cancer group, Head of the medical gyneco-oncology unit, Geneva University Hospital, Switzerland
<b>LATHOURAS KOSTANTINOS</b>	GREECE	PhD, Surgeon of Gynecologic Oncology, Director of the Gynecological Oncology Center at IASO Hospital, Honorary Senior Clinical Lecturer at Imperial College London
<b>LIANOS EVANGELOS</b>	GREECE	Pathologist - Oncologist, Director of the NHS, Pathological Oncology Department, General Oncology Hospital of Piraeus 'Metaxa'
<b>LIONTOS MICHAEL</b>	GREECE	Pathologist-Oncologist, Assistant Professor of Oncology, National and Kapodistrian University of Athens
<b>LORUSSO DOMENICA</b>	ITALY	MD, PhD, is Director of Gynaecological Oncology Unit at Humanitas Hospital San Pio X, Milan, and Full Professor of Obstetrics and Gynaecology, Humanitas University, Rozzano (MI)
<b>MAKRIS MARIOS GEORGIOS</b>	GREECE	MD, PhD, MSc, Obstetrician - Surgeon Gynecologist, Gynecological Oncologist (EBCOG-ESGO accredited), Director of the Gynecological Clinic, "Iatriko" Athens Medical Center

## PRESIDENTS-SPEAKERS

NAME	COUNTRY	PROFESSIONAL TITLE / AFFILIATION
<b>MEYDANLI MEHMET MUTLU</b>	TURKEY	M.D., Professor of Gynecologic Oncology, Secretary of the MEMAGO, Turkey
<b>MONTASSAR GHALLEB</b>	TUNISIA	MD, MBA, Assistant Professor in Surgical Oncology, Institute Salah Azaiez of Oncology, Faculty of Medicine, Tunis Tunisia
<b>MORICE PHILIPPE</b>	FRANCE	Professor, Department of Gynecologic Oncology, Gustave Roussy, Co-Chair ENGAGE, Past ESGO Président
<b>NELSON GREGG</b>	CANADA	MD PhD FRCSC (he/his), Professor and Deputy Head Department of Obstetrics & Gynecology, University of Calgary, Co-Chair, Enhanced Recovery Canada
<b>NIKOLAIDI MANTO ADAMANTIA</b>	GREECE	Oncologist - Pathologist, Associate Director of the 2nd Oncology Clinic, 'Mitera' Hospital, Athens
<b>ORTAC U. FIRAT</b>	TURKEY	Professor and President of Turkish Gynecologic Oncology Society
<b>OZGUL NEJAT</b>	TURKEY	Professor, Vice - President of MEMAGO
<b>PANOSKALTSIS THEODOROS</b>	GREECE	MD, PhD, FRCOG, ESPSO, Associate Professor of Gynecological Oncology, National and Kapodistrian University of Athens, 2nd University Clinic of Obstetrics-Gynecology, Aretaieio Hospital, Athens
<b>PAPADIMITRIOU CHRISTOS</b>	GREECE	Professor of the Medical School of the National and Kapodistrian University of Athens, Pathologist-Oncologist, Director of the Oncology Unit at Aretaieio Hospital
<b>PAPAGEORGIU MARIA</b>	GREECE	Patient Advocate. Founding Member of the Patient Group for Gynecological Cancer, "Erifyli"
<b>PAPAGEORGIU THEOHARIS</b>	GREECE	Assistant Professor of Obstetrics & Gynecology, National and Kapodistrian University of Athens, Associate of IASO Maternity Hospital
<b>PAPANIKOLAOU ALEXIOS</b>	GREECE	Professor of Obstetrics and Gynecology, 2nd Obstetrics-Gynecology Clinic, Aristotle University of Thessaloniki, Hippokration Hospital, Thessaloniki
<b>PAPATHEODOROU DIMITRIOS</b>	GREECE	Surgeon Gynecologist Oncologist, Scientific Director of the Gynecology Department at the General Cancer Oncology Hospital of Athens 'Agios Savvas', Athens
<b>PARASKEVAIDIS EVANGELOS</b>	GREECE	Professor of Obstetrics-Gynecology, School of Medicine, University of Ioannina, President of the Hellenic Society for Colposcopy & Cervical Pathology (HSCCP), President of the HeCPa Group, Ioannina
<b>PERGIALIOTIS VASILIOS</b>	GREECE	Obstetrician-Gynecologist, Assistant Professor of the 1st Obstetrics and Gynecology Clinic, National and Kapodistrian University of Athens
<b>PETOUSIS STAMATIOS</b>	GREECE	Associate Professor of Obstetrics-Gynecology, School of Medicine, Aristotle University of Thessaloniki, Specialized in Gynecological Oncology (ESGO diploma), Thessaloniki
<b>PROTOPAPAS ATHANASIOS</b>	GREECE	Professor of Obstetrics-Gynecology & Laparoscopic Surgery, 1st Obstetrics & Gynecology Clinic, National and Kapodistrian University of Athens
<b>RASHAD NOHA</b>	EGYPT	MD, Lecturer of Medical Oncology, Faculty of Medicine, Suez University, CAIRO JC Board Member
<b>RAY - COQUARD ISABELLE</b>	FRANCE	MD, PhD, Professor, President Gineco Group, President ENGOT Network, Centre Leon Berard Lyon France, Laboratoire RESHAPE U1290, Université Claude Bernard Lyon Est, France
<b>RODOLAKIS ALEXANDROS</b>	GREECE	Professor of Obstetrics - Gynecology - Gynecologic Oncology, President of the Hellenic Society of Obstetrics and Gynecology, President of the Hellenic Society of Gynecologic Oncology, Co-Member of MEMAGO, Athens
<b>SIOULAS VASILEIOS</b>	GREECE	Gynecologist Oncologist (MSKCC/ESGO), Director, 1st Department of Gynecologic Oncology, MITERA Hospital, Athens
<b>SLIMANE MAHER</b>	TUNISIA	MD
<b>SOTIROPOULOU MARIA</b>	GREECE	MD, PhD, Pathologist, 'Hygeia' Hospital
<b>STAMATAKIS EMMANUEL</b>	GREECE	Anesthesiologist, General Hospital of Athens 'Alexandra', Director of the NHS
<b>SYRIOS IOANNIS</b>	GREECE	MD, MSc, PhD, Director of the 2nd Pathological Oncology Clinic, 'Mitera' Hospital
<b>TASKIRAN CAGATAY</b>	TURKEY	MD, Professor Koc University School of Medicine and VKV American Hospital, Department of Obstetrics and Gynecology, Division of Gynecologic Oncology. Treasurer of MEMAGO





**8th MEMAGO**  
MIDDLE EAST & MEDITERRANEAN  
ASSOCIATION OF GYNECOLOGIC ONCOLOGIST &

THE 2<sup>nd</sup> ATHENS  
**OVARIAN CANCER**

**ATHENS**  
ROYAL OLYMPIC HOTEL

**SYMPOSIUM**

**28-30**  
NOVEMBER

## PRESIDENTS-SPEAKERS

NAME	COUNTRY	PROFESSIONAL TITLE / AFFILIATION
<b>TEMEL YUKSEL ILKBAL</b>	TURKEY	Associate Professor of Gynecologic Oncology, Cam Sakura City Hospital, Istanbul, Turkey
<b>THEOFANAKIS CHARALAMBOS</b>	GREECE	MD, Ph.D. Gynecologist-Oncologist (ESGO), Associate Professor of Obstetrics & Gynecology, 3rd Obstetrics & Gynecology Clinic, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens.
<b>THOMAKOS NIKOLAOS</b>	GREECE	Associate Professor of Obstetrics and Gynecology and Gynecological Oncology, National and Kapodistrian University of Athens, General Hospital of Athens 'ALEXANDRA'
<b>TSOLAKIDIS DIMITRIOS</b>	GREECE	Ass. Professor of Obstetrics and Gynecology, 1st Obstetrics and Gynecology Clinic, Aristotle University of Thessaloniki, "Papa-georgiou" Hospital, Thessaloniki
<b>VLACHOS DIMITRIOS</b>	GREECE	Obstetrician-Gynecologist, Academic Fellow, National and Kapodistrian University of Athens
<b>VLACHOS GEORGIOS</b>	GREECE	Emeritus Professor of Obstetrics and Gynecology – Gynecological Oncology, National and Kapodistrian University of Athens
<b>VORGAS GEORGIOS</b>	GREECE	Gynecological Oncologist, Doctor of Medicine from the University of Patras, Director of the Gynecology Clinic, 'Metaxa' Hospital, Athens
<b>VOULGARIS ZANNIS</b>	GREECE	Associate Professor of Gynecological Oncology, National and Kapodistrian University of Athens
<b>ZAKOPOULOU ROUBINI</b>	GREECE	MD, PhD, Medical Oncologist, Research Associate, ATTIKON general Hospital
<b>ZAPARDIEL IGNACIO</b>	SPAIN	MD, PhD, Chief Gynecologic Oncology Unit, La Paz University Hospital, Associate Professor UAM University, Madrid, Spain, Harvard Medical School GCSRT Program Graduate







## GENERAL INFORMATION

### DATES & LOCATION OF THE CONFERENCE

Thursday the 28th, Friday the 29th & Saturday the 30th of November 2024, Athens Royal Olympic Hotel

### CONFERENCE LANGUAGE

The official languages of the conference are Greek and English. No translation will be available

### EXHIBITION

During the conference, there will be an exhibition of pharmaceutical companies and medical devices.

### H.S.O.G. CREDITS

The Hellenic Society of Obstetrics and Gynecology (H.S.O.G.) will grant 3 continuing medical education credits.

### CERTIFICATE OF ATTENDANCE

Certificates of attendance will be sent electronically after the conclusion of the conference, provided that participants attend more than sixty percent (60%) of the total conference time, in accordance with the explicit guidelines of the National Organization for Medicines (E.O.F.)

### Congress Bureaus



19 Mayıs Mah. 19 Mayıs Cad. Nova Baran Center  
No: 4, 34360, Şişli / İstanbul - Türkiye  
Phone: +90 212 381 46 00 Pbx - Fax: +90 212 258 60 78  
E-mail: memago@figur.net



118 Al. Panagouli str., 153 43 Athens, Greece  
Tel.: +30 210 6074200, e-mail: md@mdcongress.gr,  
www.mdcongress.gr



**8th MEMAGO**  
MIDDLE EAST & MEDITERRANEAN  
ASSOCIATION OF GYNECOLOGIC ONCOLOGIST &

THE 2<sup>nd</sup> ATHENS  
**OVARIAN CANCER**

**ATHENS**  
ROYAL OLYMPIC HOTEL

**SYMPOSIUM**

**28-30**  
NOVEMBER

## ΧΟΡΗΓΟΙ



# The system

## CAREPAD<sup>®</sup>

DRIVING INNOVATION IN SURGERY

is an innovative system

for positioning the patient during surgical procedures performed with traditional, robotic or laparoscopic techniques. It allows a Trendelenburg positioning of the patient on the operating bed

in a safe, easy and quick manner

### Patient safety

It eliminates the risk of slippage by adapting to the shape and weight of the patient which is uniformly redistributed over the entire mat.

### Efficiency

Simple setup thanks to a patented, repeatable and safe solution. The optimal weight redistribution in the pressure zones guarantees excellent performance even without the use of shoulder pads, strips or adhesives.

### Rapidity

Pre-assembled, positionable in a few seconds and ready for use. Quick repositioning thanks to the patented solution.

### Biocompatibility<sup>1</sup>

Biocompatible<sup>1</sup> and free of latex or phthalates<sup>2</sup>, it is made of viscoelastic Memory material with slow return and high density, offering thermal insulation and anti-decubitus function.

### Trendelenburg positioning

CarePad is ideal for the patient's in Trendelenburg positioning pushed up to 45 degrees of inclination.

### Medical Device

CarePad is a Medical Device, CE marked, in accordance with Regulation (EU) 2017/745

<sup>1</sup> Biocompatibility assessed on the device, in accordance with ISO 10993-1:2018

<sup>2</sup> No substances containing latex and its derivatives or phthalates are intentionally used in its manufacture



  
**pelmyplus**  
MEDICAL

Λυκούργου 2, Νέα Ιωνία  
Τ.Κ. 142 31, Αθήνα, Ελλάδα  
Τηλ.: 216 80 90 015-16-17  
e-mail: info@pelmyplusmedical.com  
www.pelmyplusmedical.com

 **abmedica**<sup>®</sup>  
about people about health

# UNO

Μίας χρήσης Ολοκληρωμένο Σύστημα  
Αρνητικής Πίεσης 15 ημερών

